Please login to the form below

Not currently logged in
Email:
Password:

Ovarian canncer

This page shows the latest Ovarian canncer news and features for those working in and with pharma, biotech and healthcare.

Another NICE no for AZ’s new ovarian cancer drug

Another NICE no for AZ’s new ovarian cancer drug

Cost watchdog wants more information for Lynparza.  . NICE is once again saying no to AstraZeneca's new ovarian cancer drug - but is opening up a second consultation on its decision. ... The Institute is minded, in preliminary draft guidance, to reject

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics